French biotech company Amolyt Pharma Series C round fetches $138m
Amolyt Pharma, a France-based clinical-stage biotechnology company, has secured €130 million (around $138 million) from a Series C equity financing round led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). The French biotech company anticipates using the funding to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601 and […]